Fontalis, A. orcid.org/0000-0001-5547-288X, Kenanidis, E., Kotronias, R.A. et al. (4 more authors) (2019) Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. Expert Opinion on Pharmacotherapy, 20 (9). pp. 1123-1134. ISSN 1465-6566
Abstract
INTRODUCTION: Pharmacological options to address the imbalance between bone resorption and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique biologic pathways such as the Wnt/β-catenin pathway have been targeted in the quest for new emerging therapeutic strategies. Areas covered: This review provides an overview of existing pharmacotherapy for osteoporosis in women and explore state-of-the-art and emerging therapies to prevent bone loss, with an emphasis on the mechanism of action, indications and side effects. Expert opinion: Bisphosphonates appear to be a reliable and cost-effective option, whereas denosumab has introduced a simpler dosing regimen and may achieve a linear increase in bone mineral density (BMD) with no plateau being observed, along with continuous anti-fracture efficacy. Abaloparatide, a parathyroid-hormone-related peptide (PTHrP)-analogue, approved by the FDA in April 2017, constitutes the first new anabolic osteoporosis drug in the US for nearly 15 years and has also proven its anti-fracture efficacy. Romosozumab, a sclerostin inhibitor, which induces bone formation and suppresses bone resorption, has also been developed and shown a significant reduction in fracture incidence; however, concerns have arisen with regard to increased cardiovascular risk.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2019 Taylor & Francis. This is an author-produced version of a paper subsequently published in Expert Opinion on Pharmacotherapy. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Osteoporosis; abaloparatide; antiresorptive medications; osteoanabolic agents; romosozumab; sclerostin |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Oncology (Sheffield) |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 15 Apr 2019 13:50 |
Last Modified: | 23 Nov 2021 11:13 |
Status: | Published |
Publisher: | Taylor & Francis |
Refereed: | Yes |
Identification Number: | 10.1080/14656566.2019.1594772 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:144982 |